Claims for Patent: 9,678,075

Summary for Patent: 9,678,075

Title:	Prediction of recurrence for bladder cancer by a protein signature in tissue samples
Abstract:	The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.
Inventor(s):	Schroder; Christoph (Heidelberg, DE), Srinivasan; Harish (Heidelberg, DE), Hoheisel; Jorg (Wiesloch, DE), Radvanyi; Francois (Paris, FR)
Assignee:	Deutsches Krebsforschungszentrum (Heidelberg, DE) Institut Curie (Paris, FR)
Application Number:	14/124,580
Patent Claims:	1. A method for predicting the risk of recurrence of bladder cancer in a subject who has had a tumor removed by surgery, comprising: (a) determining, by immunoassay, the amounts of protein biomarkers in a tumor tissue sample from the subject who has had a tumor removed by surgery, wherein the protein biomarkers comprise Lamin A ("LMNA") and Nuclease-sensitive element-binding protein 1 ("YBX1"), wherein the immunoassay comprises: (i) contacting the sample with an antibody microarray comprising antibodies that recognize LMNA protein and antibodies that recognize YBX1; and (ii) measuring the amounts of bound protein biomarkers and thereby determining the amounts of the protein biomarkers present in the sample; (b) comparing the amounts of the protein biomarkers with a reference amount for the protein biomarkers, wherein the reference amount is derived from a subject or group of subjects known to be at risk for recurrence of bladder cancer, or from a subject or group of subjects known to not be at risk for recurrence of bladder cancer; (c) diagnosing the subject as at risk of recurrence of bladder cancer if the amounts of protein biomarkers are increased as compared to the reference amounts; and (d) treating the subject, who is at risk of recurrence of bladder cancer, with an anti-bladder cancer treatment. 2. The method of claim 1, wherein the protein biomarkers further comprise at least one additional protein biomarker selected from the group consisting of Transcription factor AP-1 ("JUN"), RAC-gamma serine/threonine-protein kinase("AKT3"), YEATS domain-containing protein 2 ("YEATS2"), GRAM domain-containing protein 1A ("GRAMD1A"), Tissue-type plasminogen activator chain B ("PLAT"), E-Cad/CTF2 ("CDH1"), Lysosome-associated membrane glycoprotein 2 ("LAMP2"), Leukemia inhibitory factor receptor ("LIFR"), DNA topoisomerase 2-alpha ("TOP2A"), Nuclear factor of activated T-cells, cytoplasmic 4 ("NFATC4"), Splicing factor 3B subunit 3 ("SF3B3"), Ubiquitin ("UBC"), Collagenase 3 ("MMP13"), Nuclear factor NF-kappa-B p105 subunit ("NFKB1"), Krueppel-like factor 5 ("KLF5"), Bc1-2-related protein A 1 ("BCL2A1"), Caspase-3 subunit p17 ("CASP3"), Transcription factor SOX-9 ("SOX9"), Mucin-5B ("MUC5B"), Aquaporin-1 ("AQP1"), Glutathione synthetase ("GSS"), Keratin, type I cytoskeletal 19 ("KRT19"), PAK-2p34 ("PAK2"), Zinc finger protein 593 ("ZNF593"), Myeloid differentiation primary response protein MyD88 ("MYD88"), Amyloid beta A4 precursor protein-binding family A member 1 ("APBA1"), Ephrin type-B receptor 3 ("EPHB3"), Interleukin-10 ("IL10"), Lymphotoxin-alpha ("LTA"), BNP(5-32) ("NPPB"), Alpha-N-acetylgalactosaminide alpha-2,6- sialyltransferase 6 ("ST6GALNAC6"), Tight junction protein Z0-2 ("TJP2"), and a combination thereof, and the subject is diagnosed as at risk of recurrence of bladder cancer if the amount of the at least one additional protein biomarker is increased as compared to the reference amount. 3. The method of claim 1, wherein the protein biomarkers further comprise at least one additional biomarker selected from the group consisting of PABPC1, SMAD3, TIA1, CDKN1A, SELL, AKTIP, HSPA8, PRIM1, RPSA, ZBTB17, SPATS2L, HLA-DMB, PTK2, IFNG, SP1, ACTN1, TIE1, TIMP1, VTN, KRT17, C9orf156, RPL10, MMP1, CDKN3, CD59, POU2F2, CDC25B, FRAP1, IRS2, ERBB2, FN1, IGLC3, AURKB, MPP3, CDKN2A, EPCAM, THBS3, CYP3A7, GRIN2C, TG, IL15, SLC7A5, POLR2C, IL8, CUL2, SEP15, TNFSF13, MAPK10, SERPINE2, HMMR, OLFM4, CS, ID2, MUTED, FAP, TNFRSF10A, KRT8, CYP1B1, BRPF3, AP4B1, GABRB1, HOXC11, PIGC, TRIM22, SPP1, and POU2F1; and the subject is diagnosed as at risk of recurrence of bladder cancer if the amount of the at least one additional biomarker is decreased as compared to the reference amount. 4. The method of claim 1, wherein the surgery is transurethral resection, radical cystectorny, or partial eystectomy. 5. The method of claim 1, further comprising determination of the level of at least one protein biomarker selected from the group consisting of AKT3, TOP2A, YETS2, Nucleolysin TIA-1 isoform p40 ("TIA1"), Cyclin-dependent kinase inhibitor 1("CDKN1A"), Mothers against decapentaplegic homolog 3 ("SMAD3"), and Polyadenylate-binding protein 1("PABP1"). 6. The method of claim 1, wherein the antibody is an antibody or functional fragment thereof and wherein the antibody or functional fragment thereof further comprises a detectable label. 7. The method of claim 1, wherein the antibody is an antibody or functional fragment thereof, and wherein the amount of the biomarker is measured by obtaining signal from the antibody or the functional fragment thereof. 8. The method of claim 1, wherein the protein biomarkers further comprise one or more biomarkers selected from the group consisting of Polyadenylate-binding protein 1 ("PABPC1"), SMAD3, TIA1, AKT3, CDKN1A, L-selectin ("SELL"), YEATS2, AKT-interacting protein ("AKTIP"), Heat shock cognate 71 kDa protein ("HSPA8"), DNA primase small subunit ("PRIM1"), 408 ribosomal protein SA ("RPSA"), GRAMD1A, PLAT, Zinc finger and BTB domain-containing protein 17 ("ZBTB17"), CDH1, LAMP2, LIFR, TOP2A, SPATS2-like protein ("SPATS2L"), NFATC4, SF3B3, UBC, HLA class II histocompatibility antigen, DM beta chain ("HLA-DMB"), Focal adhesion kinase 1 ("PTK2"), Interferon gamma ("IFNG"), Transcription factor Sp1 ("SP1"), Alpha-actinin-1("ACTN1"), Tyrosine-protein kinase receptor Tie-1 ("TIE1"), MMP13, Metalloproteinase inhibitor 1 ("TIMP1"), Somatomedin-B ("VTN"), Keratin, type I cytoskeletal 17 ("KRT17"), NFKB1, Net-associated protein 1 ("C9orf156"), 60S ribosomal protein L10 ("RPL10"), KLF5, 27 kDa interstitial collagenase ("MMP1"), Cyclin-dependent kinase inhibitor 3 ("CDKN3"), CD59 glycoprotein ("CD59"), POU domain, class 2, transcription factor 2 ("POU2F2"), M-phase inducer phosphatase 2 ("CDC25B"), Serine/threonine-protein kinase mTOR ("FRAP1"), Insulin receptor substrate 2 ("IRS2"), BCL2A1, Receptor tyrosine-protein kinase erbB-2 ("ERBB2"), CASP3, Ug1-Y2 ("FN1"), Ig lambda chain C regions ("IGLC3"), Serine/threonine-protein kinase 12 ("AURKB"), MAGUK p55 subfamily member 3 ("MPP3"), Cyclin-dependent kinase inhibitor 2A, isoform 4 ("CDKN2A"), Epithelial cell adhesion molecule ("EPCAM"), SOX9, Thrombospondin-3 ("THBS3"), MUC5B, Cytochrome P450 3A7 ("CYP3A7"), Glutamate receptor subunit epsilon-3 ("GRIN2C"), Thyroglobulin ("TG"), AQP1, Interleukin-15 ("IL15"), Large neutral amino acids transporter small subunit 1 ("SLC7A5"), GSS, ("POLR2C"), KRT19, PAK2, ZNF593, MYD88, Interleukin-8 "IL8"), Cullin-2 ("CUL2"), 15 kDa selenoprotein ("SEP15"), Tumor necrosis factor ligand superfamily member 13 ("TNFSF13"), APBA1, EPHB3, Mitogen-activated protein kinase 10 ("MAPK10"), Glia-derived nexin ("SERPINE2"), Hyaluronan mediated motility receptor ("HMMR"), IL10, Olfactomedin-4 ("OLFM4"), Citrate synthase, mitochondrial ("CS"), DNA-binding protein inhibitor ID-2 ("ID2"), Protein Muted homolog ("MUTED"), Seprase ("FAP"), Tumor necrosis factor receptor superfamily member 10A ("TNFRSF10A"), Keratin, type II cytoskeletal 8 ("KRT8"), LTA, NPPB, Cytochrome P450 1B1 ("CYP1B1"), Bromodomain and PHD finger-containing protein 3("BRPF3"), AP-4 complex subunit beta-1 ("AP4B1"), Gamma-aminobutyric acid receptor subunit beta-1 ("GABRB1"), ST6GALNAC6, Homeobox protein Hox-C11 ("HOXC11"), Phosphatidylinositol N-acetylglucosaminyltransferase subunit C ("PIGC"), Tripartite motif-containing protein 22 ("TRIM22"), Osteopontin ("SPP1"), TJP2, and POU domain, class 2, transcription factor 1 ("POU2F 1"). 9. The method of claim 1, further comprising monitoring progression of bladder cancer in the subject who is at risk of bladder cancer recurrence.

Details for Patent 9,678,075

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2031-06-10